An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Trial Profile

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Millennium
  • Most Recent Events

    • 12 Aug 2017 Data from this and other trials (NCT00963820, NCT01217957, NCT01564537) was used to quantitatively characterize the benefit-risk profile of ixazomib in relapsed/refractory MM, results published in the Targeted Oncology
    • 13 Mar 2017 Results (n=755) of pooled analysis of (C16001,C16002,C16003,C16004,C16005,C16007,C16008,C16010,C16013,TB-MC010034) ten studies assessing pharmacokinetic analysis of Ixazomib published in the Clinical Pharmacokinetics.
    • 23 Jul 2013 Planned number of patients changed from 70 to 63 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top